Black checkmark with a sparkle and a curved line underneath on a white background.
Company

DarioHealth Corp.

Ticker
DRIO
Sector
Industry
Report date
November 15, 2026
Valye AI Score

80

Very high visibility
Recent developments
Recent developments summary

Recent developments include quarterly earnings reporting improved revenue and narrowing losses, leadership appointment, and planned product launches.

Recent developments:
  • DarioHealth reported Q3 2026 revenue growth of 6% with a narrowing net loss, reflecting operational progress [N2][N3].
  • The company announced the appointment of John R. Palumbo as Chairman of the Board in November 2026 [N4].
  • Plans to launch women’s health and sleep programs in Q4 2026 were disclosed, indicating product expansion [N6].
  • Liquidity remains strong with a current ratio of 4.2 and cash ratio of 3.4 as of September 30, 2026 [S2].
Overview

DarioHealth Corp. is a digital health company focused on providing health management solutions. The company’s business model includes subscription-based digital health programs and services aimed at chronic condition management. Recent financial disclosures show ongoing investments in product development and expansion, with a focus on enhancing offerings in women’s health and sleep management. The company operates under financial covenants that require careful liquidity management.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. DarioHealth Corp. reported a net loss of $8.8 million for Q3 2026 with a 6% revenue increase. The company maintains strong liquidity with a current ratio of 4.2 as of September 30, 2026. Recent developments include leadership changes and planned product launches in women’s health and sleep programs [S2][N2][N3][N4][N6].

Scenarios for DRIO

Bull case model:

The company’s recent revenue growth and narrowing net loss indicate operational improvements. Planned launches of new health programs could diversify revenue streams and enhance customer engagement. Strong liquidity ratios provide financial flexibility to support growth initiatives and product development. Leadership changes may bring strategic focus and governance enhancements.

Bear case model:

The company faces risks related to compliance with financial covenants under its credit facility, which could impact liquidity and operational flexibility if not managed effectively. Continued net losses highlight ongoing profitability challenges. Market competition in digital health and the need for sustained investment in product innovation present execution risks. Dependence on equity cures or amendments to credit agreements may pose financial uncertainty.

Moat:

DarioHealth’s moat is based on its integrated digital health platform that combines technology, data analytics, and personalized health management programs. Its focus on chronic disease management and expansion into specialized health programs such as women’s health and sleep positions it within a niche digital health market. The company’s ability to maintain compliance with financial covenants and sustain liquidity supports ongoing operational stability.

Risks overview
Risks summary
The primary risk is maintaining compliance with financial covenants under the credit facility, which affects liquidity and operational flexibility.
Risks details:

• Financial Covenant Compliance Risk: The company did not satisfy one of the financial covenants under its Credit Agreement as of September 30, 2026, and relies on equity cures to maintain compliance. Failure to comply could lead to an Event of Default, accelerating debt and impacting liquidity and operations [S2].
• Profitability Challenges: DarioHealth reported a net loss of $8.8 million for Q3 2026, indicating ongoing challenges in achieving profitability despite revenue growth [S2][N2].
• Market Competition and Execution Risk: The digital health sector is competitive, requiring continuous innovation and effective execution to maintain and grow market share. Expansion into new health programs carries execution risks [N6].

FINAL FORECAST FOR DRIO

Final take one line
DarioHealth Corp. shows strong liquidity and operational progress with recent revenue growth and product expansion amid financial covenant compliance risks.
Final take 12 to 24 month view

Business trends: Revenue growth with narrowing losses and expansion into women’s health and sleep programs.
Execution milestones: Appointment of new Chairman and planned product launches in Q4 2026.
Key risks: Compliance with financial covenants under credit agreements and ongoing profitability challenges.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

80
LLM visibility overview
LLM Visibility known facts
  • DarioHealth Corp. operates in the digital health sector with a focus on health management solutions.
  • As of September 30, 2026, the company reported cash and cash equivalents of $27.8 million and short-term investments of $3.3 million, totaling approximately $31.1 million in liquid assets.
  • Current assets as of September 30, 2026, were $38.5 million, with current liabilities of $9.2 million, resulting in a current ratio of 4.2 and a cash ratio of 3.4, indicating strong short-term liquidity.
  • The company reported a net loss of $8.8 million for the quarter ended September 30, 2026, with basic and diluted earnings per share of $0.73.
  • DarioHealth's Q3 2026 revenue increased by 6% compared to prior periods, with the company reporting revenue growth alongside a narrowing net loss.
  • The company announced plans to launch new women’s health and sleep programs in Q4 2026, indicating product expansion efforts.
  • John R. Palumbo was appointed as Chairman of the Board in November 2026, reflecting recent leadership changes.
  • The company is subject to financial covenants under a Credit Agreement with Callodine Commercial Finance, LLC, and as of September 30, 2026, it had exercised an Equity Cure right to comply with these covenants.
  • There is risk related to future compliance with financial covenants, which could affect liquidity and operational flexibility if not managed properly.
  • Recent earnings calls and reports provide detailed insights into financial performance and strategic initiatives for 2026.
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
  • N1
  • N7
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-19 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-12 | www.nasdaq.com | DarioHealth (DRIO) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/dariohealth-drio-q3-2026-earnings-call-transcript
  • N2 | 2026-11-12 | www.nasdaq.com | DarioHealth Corp Q3 Net Loss Narrows As Revenue Rises 6% | https://www.nasdaq.com/articles/dariohealth-corp-q3-net-loss-narrows-revenue-rises-6
  • N3 | 2026-11-12 | www.nasdaq.com | DarioHealth Corp. (DRIO) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/dariohealth-corp-drio-reports-q3-loss-tops-revenue-estimates
  • N4 | 2026-11-06 | www.nasdaq.com | DarioHealth Corp. Appoints John R. Palumbo as Chairman of the Board | https://www.nasdaq.com/articles/dariohealth-corp-appoints-john-r-palumbo-chairman-board
  • N5 | 2026-11-05 | www.nasdaq.com | Globus Medical (GMED) Q3 Earnings Top Estimates | https://www.nasdaq.com/articles/globus-medical-gmed-q3-earnings-top-estimates
  • N6 | 2026-08-12 | www.nasdaq.com | DarioHealth Q2 Loss Narrows Despite Revenue Decline; To Launch Women And Sleep Programs In Q4 '26 | https://www.nasdaq.com/articles/dariohealth-q2-loss-narrows-despite-revenue-decline-launch-women-and-sleep-programs-q4-26
  • N7 | 2026-08-12 | www.nasdaq.com | DarioHealth (DRIO) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/dariohealth-drio-q2-2026-earnings-call-transcript
  • N8 | 2026-08-11 | www.nasdaq.com | DarioHealth Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/dariohealth-q2-earnings-call-highlights
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine